Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + R-miniCHOP in DLBCL patients aged 80 or older
NCT02128061Phase 3Completed
- Sponsor
- LYSARC
- Start
- Aug 2014
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by LYSARC. Started Aug 2014; status: completed.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02128061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02128061.